Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses
- PMID: 37762191
- PMCID: PMC10531407
- DOI: 10.3390/ijms241813888
Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses
Abstract
Pandemic and epidemic outbreaks of respiratory viruses are a challenge for public health and social care system worldwide, leading to high mortality and morbidity among the human populations. In light of the limited efficacy of current vaccines and antiviral drugs against respiratory viral infections and the emergence and re-emergence of new viruses, novel broad-spectrum antiviral drugs are needed for the prevention and treatment of these infections. Antimicrobial peptides with an antiviral effect, also known as AVPs, have already been reported as potent inhibitors of viral infections by affecting different stages of the virus lifecycle. In the present study, we analyzed the activity of the AVP Hylin-a1, secreted by the frog Hypsiboas albopunctatus, against a wide range of respiratory viruses, including the coronaviruses HCoV-229E and SARS-CoV-2, measles virus, human parainfluenza virus type 3, and influenza virus H1N1. We report a significant inhibitory effect on infectivity in all the enveloped viruses, whereas there was a lack of activity against the naked coxsackievirus B3. Considering the enormous therapeutic potential of Hylin-a1, further experiments are required to elucidate its mechanism of action and to increase its stability by modifying the native sequence.
Keywords: SARS-CoV-2; antimicrobial peptide; coronavirus; emerging infection; influenza; inhibitory peptide; respiratory viruses.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.Virol J. 2020 Sep 9;17(1):136. doi: 10.1186/s12985-020-01401-2. Virol J. 2020. PMID: 32907596 Free PMC article.
-
The antiherpetic and anti-inflammatory activity of the frog-derived peptide Hylin-a1.J Appl Microbiol. 2024 Jul 2;135(7):lxae165. doi: 10.1093/jambio/lxae165. J Appl Microbiol. 2024. PMID: 38991986
-
Virucidal activity of tiliacorinine, dioscorine, racemosol, and terrein against influenza A virus (H1N1), coronavirus 229E, SARS-CoV-2, and enterovirus 71.J Infect Public Health. 2025 Apr;18(4):102699. doi: 10.1016/j.jiph.2025.102699. Epub 2025 Feb 11. J Infect Public Health. 2025. PMID: 39970852
-
Current Strategies of Antiviral Drug Discovery for COVID-19.Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021. Front Mol Biosci. 2021. PMID: 34055887 Free PMC article. Review.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
Cited by
-
SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection.Pharmaceutics. 2023 Dec 17;15(12):2791. doi: 10.3390/pharmaceutics15122791. Pharmaceutics. 2023. PMID: 38140131 Free PMC article.
-
Frog Skin Peptides Hylin-a1, AR-23, and RV-23: Promising Tools Against Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae Infections.Antibiotics (Basel). 2025 Apr 3;14(4):374. doi: 10.3390/antibiotics14040374. Antibiotics (Basel). 2025. PMID: 40298508 Free PMC article.
-
A Cyclic Peptide Based on Pheasant Cathelicidin Inhibits Influenza A H1N1 Virus Infection.Antibiotics (Basel). 2024 Jun 28;13(7):606. doi: 10.3390/antibiotics13070606. Antibiotics (Basel). 2024. PMID: 39061288 Free PMC article.
-
The Therapeutic Potential of Antimicrobial Peptides Isolated from the Skin Secretions of Anurans of the Genus Boana in the Face of the Global Antimicrobial Resistance Crisis.Toxins (Basel). 2025 Jun 20;17(7):312. doi: 10.3390/toxins17070312. Toxins (Basel). 2025. PMID: 40711125 Free PMC article. Review.
-
The application and prospects of antimicrobial peptides in antiviral therapy.Amino Acids. 2024 Dec 4;56(1):68. doi: 10.1007/s00726-024-03427-0. Amino Acids. 2024. PMID: 39630161 Free PMC article. Review.
References
-
- Wang X., Li Y., O’Brien K.L., Madhi S.A., Widdowson M.-A., Byass P., Omer S.B., Abbas Q., Ali A., Amu A., et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study. Lancet Glob. Health. 2020;8:e497–e510. doi: 10.1016/s2214-109x(19)30545-5. - DOI - PMC - PubMed
-
- Blau D.M., Baillie V.L., Els T., Mahtab S., Mutevedzi P., Keita A.M., Kotloff K.L., Mehta A., Sow S.O., Tapia M.D., et al. Deaths Attributed to Respiratory Syncytial Virus in Young Children in High–Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS) Clin. Infect. Dis. 2021;73((Suppl. S3)):S218–S228. doi: 10.1093/cid/ciab509. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- CUP B63C22001230002/Realizzazione di Servizi di Ricerca e Sviluppo per la Lotta contro il COVID-19"
- 2017M8R7N9/PRIN 2017 "Natural and pharmacological inhibition of the early phase of viral replication (Vir-SudNet)"
- PE00000007, INF-ACT/NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous